-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec
inFerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec …
0 -
Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients
inFerring and Blackstone Life Sciences invest over $570 million USD in novel…
-
Wprowadzenie na rynek leku CLENPIQ® (pikosiarczan sodu, tlenek magnezu i bezwodny kwas cytrynowy).
TIMELINES onin -
Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth
inFerring Pharmaceuticalstoday welcomes the World Health Organization’s (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML)…
-
Ferring announces changes to Executive Committee
inFerring Pharmaceuticals announced today that Lars Peter Brunse is retiring from his role as Executive Vice President and Chief Production Officer. Armin Metzger, previously Senior Vice President, Head of Global Pharmaceutical R&D, has been appointed
-
Ferring collaboration with digital health innovators WOOM aims to help more people build families faster
inFerring Pharmaceuticals and WOOM today announced a collaboration, which aims to improve and shorten the fertility journeys of the one in six couples who have difficulty conceiving…
-
Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries
inFerring welcomes the recent update to the World Health Organization (WHO) recommendations relating to uterotonics for the prevention of postpartum haemorrhage (PPH), with specific…
-
Ferring, Rebiotix and Karolinska Institutet extend collaboration to research next generation of microbiome treatments
inFerring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology.
-
Launch of Clenpiq® (sodium picosulfate, magnesium oxide, and anhydrous citric acid)
TIMELINES oninLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
-
Ferring announces recipients of 2018-19 Innovation Grants
inFerring Pharmaceuticals today announced the recipients of the 2018-19 Ferring Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.
Archiwum Autora pulse
Articles by: pulse